Innoviva to Participate in Upcoming Investor Conferences
Innoviva, Inc. (NASDAQ: INVA), a diversified holding company, has announced its participation in two upcoming investor conferences in September 2024. The company will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Tuesday, September 10, at 10:30 a.m. Eastern Time. Additionally, Innoviva will participate in a fireside chat at the 2024 Cantor Fitzgerald Global Healthcare Conference on Wednesday, September 18, at 3:40 p.m. Eastern Time.
Both presentations will be accessible via live webcasts in the Investor Relations section of Innoviva's website. Archived replays will also be available after the events. This participation demonstrates Innoviva's commitment to engaging with investors and showcasing its portfolio, which includes a core royalties segment and a critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST).
Innoviva, Inc. (NASDAQ: INVA), una società diversificata, ha annunciato la sua partecipazione a due conferenze per investitori in programma a settembre 2024. L'azienda presenterà al 26° Annual Global Investment Conference di H.C. Wainwright martedì 10 settembre, alle 10:30 ora orientale. Inoltre, Innoviva parteciperà a una chiacchierata informale al 2024 Cantor Fitzgerald Global Healthcare Conference mercoledì 18 settembre, alle 15:40 ora orientale.
Entrambe le presentazioni saranno accessibili tramite webcast dal vivo nella sezione Relazioni con gli Investitori del sito web di Innoviva. Le registrazioni archiviate saranno disponibili anche dopo gli eventi. Questa partecipazione dimostra l'impegno di Innoviva nel dialogo con gli investitori e nella presentazione del suo portafoglio, che include un segmento core di royalties e una piattaforma per la terapia intensiva e le malattie infettive conosciuta come Innoviva Specialty Therapeutics (IST).
Innoviva, Inc. (NASDAQ: INVA), una empresa diversificada, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024. La compañía presentará en la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright el martes 10 de septiembre a las 10:30 a.m. hora del Este. Además, Innoviva participará en un chat informal en la Conferencia Global de Salud 2024 de Cantor Fitzgerald el miércoles 18 de septiembre a las 3:40 p.m. hora del Este.
Ambas presentaciones estarán disponibles a través de transmisiones web en vivo en la sección de Relaciones con Inversores del sitio web de Innoviva. También estarán disponibles repeticiones archivadas después de los eventos. Esta participación demuestra el compromiso de Innoviva con el compromiso con los inversores y la exhibición de su portafolio, que incluye un segmento principal de regalías y una plataforma de cuidados críticos y enfermedades infecciosas conocida como Innoviva Specialty Therapeutics (IST).
Innoviva, Inc. (NASDAQ: INVA)는 다각화된 지주 회사로, 2024년 9월에 예정된 두 개의 투자자 회의에 참여할 것이라고 발표했습니다. 이 회사는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에서 9월 10일 화요일 오전 10시 30분 동부 표준시(EST)에 발표할 예정입니다. 또한 Innoviva는 2024 캔터 피츠제럴드 글로벌 헬스케어 회의에서 9월 18일 수요일 오후 3시 40분 동부 표준시(EST)에 소규모 대화에 참여할 것입니다.
두 발표 모두 Innoviva 웹사이트의 투자자 관계 섹션을 통해 실시간 웹캐스트로 접속할 수 있습니다. 이벤트 후에는 아카이브된 재생도 가능할 것입니다. 이 참여는 Innoviva가 투자자와의 소통에 대한 의지와 혁신적인 로열티 부문 및 Innoviva Specialty Therapeutics (IST)로 알려진 중환자 치료 및 감염병 플랫폼을 포함한 포트폴리오를 선보이려는 노력을 보여줍니다.
Innoviva, Inc. (NASDAQ: INVA), une société holding diversifiée, a annoncé sa participation à deux conférences pour investisseurs prévues en septembre 2024. L'entreprise présentera lors de la 26e Conférence Annuelle Mondiale des Investissements de H.C. Wainwright le mardi 10 septembre à 10h30, heure de l'Est. De plus, Innoviva participera à une discussion informelle lors de la Conférence Mondiale sur la Santé 2024 de Cantor Fitzgerald le mercredi 18 septembre à 15h40, heure de l'Est.
Les deux présentations seront accessibles par le biais de webcasts en direct dans la section Relations avec les Investisseurs du site Web d'Innoviva. Des rediffusions archivées seront également disponibles après les événements. Cette participation démontre l'engagement d'Innoviva à interagir avec les investisseurs et à présenter son portefeuille, qui comprend un segment principal de redevances et une plateforme de soins critiques et de maladies infectieuses connue sous le nom d'Innoviva Specialty Therapeutics (IST).
Innoviva, Inc. (NASDAQ: INVA), ein diversifiziertes Holdingunternehmen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird am 26. jährlichen Global Investment Conference von H.C. Wainwright am Dienstag, den 10. September, um 10:30 Uhr Eastern Time präsentieren. Darüber hinaus wird Innoviva an einem informellen Gespräch auf der 2024 Cantor Fitzgerald Global Healthcare Conference am Mittwoch, den 18. September, um 15:40 Uhr Eastern Time teilnehmen.
Beide Präsentationen werden über Live-Webcasts im Bereich Investor Relations auf der Website von Innoviva zugänglich sein. Auch archivierte Wiederholungen werden nach den Veranstaltungen verfügbar sein. Diese Teilnahme zeigt Innovivas Engagement, mit Investoren in Kontakt zu treten und sein Portfolio zu präsentieren, das ein Kernsegment für Lizenzgebühren sowie eine Plattform für kritische Versorgung und Infektionskrankheiten umfasst, die als Innoviva Specialty Therapeutics (IST) bekannt ist.
- None.
- None.
H.C. Wainwright 26th Annual Global Investment Conference
Format: Corporate Presentation
Date: Tuesday, September 10, 2024
Time: 10:30 a.m. Eastern Time
2024 Cantor Fitzgerald Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 18, 2024
Time: 3:40 p.m. Eastern Time
Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at https://investor.inva.com/presentations-events. Archived replays of the webcasts will be available following the presentation dates.
About Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904577524/en/
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
FAQ
When is Innoviva (INVA) participating in the H.C. Wainwright Global Investment Conference?
What type of presentation will Innoviva (INVA) give at the Cantor Fitzgerald Global Healthcare Conference?
Where can investors access the webcasts of Innoviva's (INVA) conference presentations?
What are the main business segments of Innoviva (INVA)?
